Anebulo Pharmaceuticals, Inc. SEC filings ANEB

Anebulo Pharmaceuticals, Inc. has 204 filings in SEC EDGAR's recent list, going back to Jun 25, 2020. Its latest annual report, Form 10-K, was filed on Sep 29, 2025 for the period ended Jun 30, 2025. The latest quarterly report (Form 10-Q) was filed on Feb 12, 2026, covering the quarter ended Dec 31, 2025. The most recent current report (Form 8-K) was filed on Feb 12, 2026 (results of operations). The company's fiscal year ends on June 30.

Anebulo Pharmaceuticals, Inc. SEC filings
Form Description Filed Period
15-12G Deregistration Mar 2, 2026 —
25 Filing Feb 17, 2026 —
10-Q Quarterly report Feb 12, 2026 Dec 31, 2025
8-K Current report
Results of operations
Feb 12, 2026 Feb 12, 2026
8-K Current report
Listing notice, Other events
Feb 6, 2026 Feb 5, 2026
8-K Current report
Other events
Jan 29, 2026 Jan 29, 2026
8-K Current report
Other events
Jan 27, 2026 Jan 26, 2026
CORRESP Letter to the SEC Jan 8, 2026 —
UPLOAD Letter from the SEC Dec 31, 2025 —
SC TO-I Filing Dec 22, 2025 —
8-K Current report
Other events
Dec 22, 2025 Dec 22, 2025
10-Q Quarterly report Nov 13, 2025 Sep 30, 2025
8-K Current report
Results of operations
Nov 13, 2025 Nov 13, 2025
CORRESP Letter to the SEC Oct 10, 2025 —
PRER14A Filing Oct 10, 2025 —
10-K Annual report Sep 29, 2025 Jun 30, 2025
8-K Current report
Results of operations
Sep 29, 2025 Sep 29, 2025
S-8 POS Filing Sep 26, 2025 —
S-8 POS Filing Sep 26, 2025 —
EFFECT Filing Sep 23, 2025 —
EFFECT Filing Sep 23, 2025 —
UPLOAD Letter from the SEC Sep 22, 2025 —
POS AM Filing Sep 19, 2025 —
POS AM Filing Sep 19, 2025 —
CORRESP Letter to the SEC Sep 15, 2025 —
PRER14A Filing Sep 15, 2025 —
8-K Current report
Other events
Sep 12, 2025 Sep 12, 2025
UPLOAD Letter from the SEC Aug 14, 2025 —
8-K Current report
Other events
Jul 23, 2025 Jul 23, 2025
PRE 14A Preliminary proxy statement Jul 23, 2025 Jul 23, 2025
S-8 Employee stock plan registration May 15, 2025 —
10-Q Quarterly report May 13, 2025 Mar 31, 2025
8-K Current report
Results of operations
May 13, 2025 May 13, 2025
8-K Current report
Other events
Apr 15, 2025 Apr 11, 2025
8-K Current report
Bylaw or fiscal year change
Apr 14, 2025 Apr 11, 2025
8-K Current report
Officer or director change, Shareholder vote results
Apr 7, 2025 Apr 4, 2025
ARS Annual report to shareholders Mar 6, 2025 Jun 30, 2024
DEF 14A Proxy statement Mar 6, 2025 Mar 6, 2025
424B5 Prospectus supplement Mar 3, 2025 —
EFFECT Filing Feb 28, 2025 —
CORRESP Letter to the SEC Feb 26, 2025 —
UPLOAD Letter from the SEC Feb 25, 2025 —
PRE 14A Preliminary proxy statement Feb 24, 2025 Feb 24, 2025
8-K Current report
Material agreement, Listing notice
Feb 24, 2025 Feb 20, 2025
S-3 Shelf registration Feb 20, 2025 —
10-Q Quarterly report Feb 14, 2025 Dec 31, 2024
8-K Current report
Results of operations
Feb 14, 2025 Feb 14, 2025
8-K Current report
Other events
Feb 12, 2025 Feb 11, 2025
D Filing Dec 31, 2024 —
8-K Current report
Material agreement, Unregistered share sale, Change in control, Other events
Dec 23, 2024 Dec 22, 2024
10-Q Quarterly report Nov 13, 2024 Sep 30, 2024
8-K Current report
Results of operations
Nov 13, 2024 Nov 13, 2024
8-K Current report
Regulation FD disclosure
Oct 17, 2024 Oct 17, 2024
10-K Annual report Sep 25, 2024 Jun 30, 2024
8-K Current report
Results of operations
Sep 25, 2024 Sep 25, 2024
8-K Current report
Other events
Jul 22, 2024 Jul 22, 2024
8-K Current report
Other events
Jun 17, 2024 Jun 13, 2024
10-Q Quarterly report May 15, 2024 Mar 31, 2024
8-K Current report
Results of operations
May 15, 2024 May 15, 2024
10-Q Quarterly report Feb 13, 2024 Dec 31, 2023
8-K Current report
Results of operations
Feb 13, 2024 Feb 13, 2024
8-K Current report
Shareholder vote results
Nov 21, 2023 Nov 20, 2023
10-Q Quarterly report Nov 14, 2023 Sep 30, 2023
8-K Current report
Results of operations
Nov 14, 2023 Nov 14, 2023
ARS Annual report to shareholders Oct 30, 2023 Jun 30, 2023
DEF 14A Proxy statement Oct 30, 2023 Oct 30, 2023
PRE 14A Preliminary proxy statement Oct 19, 2023 Oct 19, 2023
8-K Current report
Officer or director change
Oct 6, 2023 Oct 5, 2023
8-K Current report
Officer or director change
Sep 29, 2023 Sep 26, 2023
10-K Annual report Sep 22, 2023 Jun 30, 2023
8-K Current report
Results of operations
Sep 20, 2023 Sep 20, 2023
8-K Current report
Agreement ended, Officer or director change
Sep 5, 2023 Aug 29, 2023
10-Q Quarterly report May 11, 2023 Mar 31, 2023
8-K Current report
Results of operations
May 11, 2023 May 11, 2023
8-K Current report
Other events
Apr 11, 2023 Apr 11, 2023
8-K Current report
Other events
Mar 28, 2023 Mar 28, 2023
8-K Current report
Material agreement, Officer or director change
Mar 8, 2023 Mar 2, 2023
10-Q Quarterly report Feb 10, 2023 Dec 31, 2022
8-K Current report
Results of operations
Feb 10, 2023 Feb 10, 2023
8-K Current report
Results of operations, Regulation FD disclosure, Other events
Jan 9, 2023 Jan 9, 2023
EFFECT Filing Nov 10, 2022 —
10-Q Quarterly report Nov 10, 2022 Sep 30, 2022
8-K Current report
Results of operations
Nov 10, 2022 Nov 10, 2022
CORRESP Letter to the SEC Nov 8, 2022 —
UPLOAD Letter from the SEC Nov 8, 2022 —
S-1 Registration statement Nov 2, 2022 —
8-K Current report
Shareholder vote results
Oct 28, 2022 Oct 28, 2022
DEFR14A Filing Oct 25, 2022 —
DEF 14A Proxy statement Oct 17, 2022 Oct 17, 2022
8-K Current report
Bylaw or fiscal year change
Oct 13, 2022 Oct 11, 2022
D Filing Oct 11, 2022 —
8-K Current report
Unregistered share sale
Sep 29, 2022 Sep 25, 2022
8-K Current report
Regulation FD disclosure, Other events
Sep 26, 2022 Sep 26, 2022
10-K Annual report Sep 9, 2022 Jun 30, 2022
8-K Current report
Results of operations
Sep 9, 2022 Sep 9, 2022
8-K Current report
Regulation FD disclosure
Jul 5, 2022 Jul 5, 2022
8-K Current report
Officer or director change
May 24, 2022 May 24, 2022
10-Q Quarterly report May 11, 2022 Mar 31, 2022
8-K Current report
Results of operations
May 11, 2022 May 11, 2022
S-8 Employee stock plan registration Apr 22, 2022 —
8-K Current report
Other events
Apr 1, 2022 Apr 1, 2022
10-Q Quarterly report Feb 11, 2022 Dec 31, 2021
8-K Current report
Results of operations
Feb 11, 2022 Feb 11, 2022
8-K Current report
Officer or director change
Jan 5, 2022 Dec 31, 2021
8-K Current report
Other events
Jan 3, 2022 Jan 3, 2022
8-K Current report
Shareholder vote results
Nov 16, 2021 Oct 22, 2021
10-Q Quarterly report Nov 12, 2021 Sep 30, 2021
8-K Current report
Results of operations
Nov 12, 2021 Nov 12, 2021
DEFA14A Additional proxy material Sep 22, 2021 —
DEF 14A Proxy statement Sep 22, 2021 Sep 22, 2021
10-K Annual report Sep 22, 2021 Jun 30, 2021
8-K Current report
Results of operations
Sep 22, 2021 Sep 22, 2021
10-Q Quarterly report Jun 21, 2021 Mar 31, 2021
424B4 Prospectus May 10, 2021 —
CERT Filing May 7, 2021 —
EFFECT Filing May 6, 2021 —
CORRESP Letter to the SEC May 5, 2021 —
CORRESP Letter to the SEC May 5, 2021 —
8-A12B Filing May 5, 2021 —
CORRESP Letter to the SEC May 5, 2021 —
S-1/A Amended registration statement May 5, 2021 —
UPLOAD Letter from the SEC May 4, 2021 —
FWP Free writing prospectus Apr 26, 2021 —
CORRESP Letter to the SEC Apr 26, 2021 —
S-1/A Amended registration statement Apr 26, 2021 —
UPLOAD Letter from the SEC Apr 15, 2021 —
CORRESP Letter to the SEC Apr 1, 2021 —
S-1 Registration statement Apr 1, 2021 —
UPLOAD Letter from the SEC Mar 25, 2021 —
DRS/A Filing Mar 12, 2021 —
DRSLTR Filing Mar 11, 2021 —
UPLOAD Letter from the SEC Feb 26, 2021 —
DRSLTR Filing Jan 29, 2021 —
DRS Filing Jan 29, 2021 —
D Filing Jun 25, 2020 —

Showing 135 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ANEB (OTC)
Fiscal year ends
June 30
Incorporated in
DE
Headquarters
Lakeway, TX
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1815974

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.